Lanier Biotherapeutics advances medical treatments to improve quality of living

We discover and develop antibody treatments to restore and improve better health: seeing, breathing, and believing!

A portfolio in focus

Seeing the bigger picture

Immuno-Oncology

Proprietary antibody offerings.

MT-6402 in the clinic with Molecular Templates.

Type 2 Inflammation

Moderate-to-severe conditions, like asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis and food allergies, with limited response to corticosteroid treatment.

Retinal

Biobetter multifunctional anti-VEGF antibodies.

A portfolio in focus

Seeing the bigger picture

Retinal

Biobetter multifunctional anti-VEGF antibodies.

Type 2 Inflammation

Moderate-to-severe conditions, like asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis and food allergies, with limited response to corticosteroid treatment.

Immuno-Oncology

Proprietary antibody offerings.

MT-6402 in the clinic with Molecular Templates.

Meet our team

Lanier Biotherapeutics is composed of some of the best minds in biotherapeutics. Visionaries with decades of experience and a dedication to advancing treatment for retinal, dermatological and respiratory diseases.
null

Daniel White

Chief Executive Officer & Director
null

Kirby Alton

Chairman
null

Martin Simonetti

Director
Chris McLeod

Christopher McLeod

Director

Investors

Lanier Biotherapeutics is funded by a group of visionary private investors

If you are interested in further exploring as an investor, please contact us.

Connect with us

Corporate Office

150 Ben Burton Rd,
Bogart, GA, 30622, USA 

Send message